#AS­CO22: Fol­low­ing back-to-back TIG­IT bombs, Roche of­fers in­sight in­to first PhI­II tri­al fail

Roche’s Genen­tech suf­fered two con­sec­u­tive Phase III fails for tiragolum­ab, the ear­li­est in a se­ries of an­ti-TIG­IT drugs from Big Phar­mas hop­ing to ush­er in the next gen­er­a­tion of im­mune check­point ther­a­pies.

To­day, the Swiss phar­ma un­veiled spe­cif­ic da­ta on SKY­SCRAPER-02, the first tri­al that flopped, which test­ed tiragolum­ab along­side Tecen­triq and chemother­a­py as a first line of treat­ment in pa­tients with ex­ten­sive stage small cell lung can­cer. Com­pared to an av­er­age over­all sur­vival of 12.9 months with on­ly Tecen­triq and chemother­a­py, the ad­di­tion of tiragolum­ab failed to move the nee­dle at all, with an over­all sur­vival of 13.1 months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER